Form D · Biotechnology

Virion Therapeutics, LLC

Newark, DE · CIK 0001746726

Offering snapshot reported Oct 7, 2021 · SEC filing

Reported sold
$5.67M
Offering amount: $6M
Investors reported
49
Form D · investor count
Minimum accepted
$25K
Reported outside-investor minimum
First sale
Oct 28, 2019
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$2.83M$5.67MNov 4, 2019: $250,000.00Nov 4, 2019Jan 6, 2020: $495,000.00Mar 18, 2020: $695,000.00May 20, 2020: $545,000.00Jul 28, 2020: $595,000.00Aug 13, 2020: $695,000.00Sep 17, 2020: $960,000.00Oct 20, 2020: $1,095,000.00Nov 5, 2020: $1,295,000.00Jan 4, 2021: $1,125,000.00Jan 21, 2021: $1,238,333.00Feb 24, 2021: $1,913,358.00Mar 12, 2021: $2,825,858.00Jun 8, 2021: $3,060,858.00Aug 11, 2021: $3,380,858.00Aug 25, 2021: $3,880,858.00Oct 7, 2021: $5,669,858.00Oct 7, 2021

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$3,380,858 → $5,669,858
  • Reported investors37 → 49

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Oct 7, 2021Amendment$5,669,858$2,289,000vs Aug 11, 202149SEC filing
Aug 25, 2021Amendment$3,880,858$500,000vs Aug 11, 202140SEC filing
Aug 11, 2021Amendment$3,380,858$320,000vs Jun 8, 202137SEC filing
Jun 8, 2021Amendment$3,060,858$235,000vs Mar 12, 202134SEC filing
May 13, 2021Amendment$2,955,858No comparisonNot reportedSEC filing
Mar 12, 2021Amendment$2,825,858$912,500vs Feb 24, 202132SEC filing
Feb 24, 2021Amendment$1,913,358$675,025vs Jan 21, 202131SEC filing
Jan 21, 2021Amendment$1,238,333$113,333vs Jan 4, 202125SEC filing
Jan 4, 2021Amendment$1,125,000$30,000vs Oct 20, 202022SEC filing
Nov 5, 2020Amendment$1,295,000$200,000vs Oct 20, 202023SEC filing
Oct 20, 2020Amendment$1,095,000$135,000vs Sep 17, 202020SEC filing
Sep 17, 2020Amendment$960,000$265,000vs Aug 13, 202016SEC filing
Aug 13, 2020Amendment$695,000$100,000vs Jul 28, 20209SEC filing
Jul 28, 2020Amendment$595,000$50,000vs May 20, 20208SEC filing
May 20, 2020Amendment$545,000$50,000vs Jan 6, 20207SEC filing
Mar 18, 2020Amendment$695,000$200,000vs Jan 6, 202011SEC filing
Jan 6, 2020Amendment$495,000$245,000vs Nov 4, 20197SEC filing
Nov 4, 2019Initial$250,000No comparison4SEC filing
Nov 27, 2018Amendment$5,231,402$75,000vs Oct 9, 201880SEC filing
Oct 9, 2018Amendment$5,156,402$305,000vs Sep 21, 201878SEC filing
Sep 21, 2018Amendment$4,851,402$1,115,000vs Aug 2, 201878SEC filing
Sep 4, 2018Amendment$4,051,402$315,000vs Aug 2, 201870SEC filing
Aug 2, 2018Amendment$3,736,402$1,617,500vs Jul 24, 201865SEC filing
Jul 24, 2018Amendment$2,118,902$0vs Jul 19, 201835SEC filing
Jul 19, 2018Initial$2,118,902No comparison35SEC filing

Offering details

Securities
Debt
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-352490

Source: Form D, filed Oct 7, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Andrew Luber Director, Executive
Bernard Rudnick Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
7 Creek Bend Court
Newark, DE, 19711